002620 — Jeil Pharma Holdings Cashflow Statement

0.000.00%

Last trade - 00:00

HealthcareAdventurousSmall CapValue Trap

Annual cashflow statement for Jeil Pharma Holdings, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st	2025 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	ARS
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Net Income/Starting Line	-12,870	-83,145	-13,241	-66,391	34,647
Depreciation
Amortisation
Non-Cash Items	10,760	77,504	28,548	59,389	-9,993
Unusual Items
Purchased R&D
Equity in Net Earnings/Losses
Other Non-Cash Items
Changes in Working Capital	6,530	-26,066	-32,279	-2,555	-39,213
Change in Accounts Receivable
Change in Inventories
Change in Prepaid Expenses
Change in Other Assets
Change in Accounts Payable
Change in Other Liabilities
Other Operating Cash Flow
Cash from Operating Activities	13,403	-20,802	-4,416	4,542	390
Capital Expenditures	-23,736	-21,410	-9,837	-6,863	-9,328
Purchase of Fixed Assets
Purchase / Acquisition of Intangibles
Other Investing Cash Flow Items	31,061	3,846	-3,588	9,137	-5,300
Sale of Fixed Assets
Sale/Maturity of Investment
Change in Net Investments
Purchase of Investments
Sale of Intangible Assets
Other Investing Cash Flow
Cash from Investing Activities	7,325	-17,564	-13,425	2,274	-14,628
Financing Cash Flow Items	-810	—	—	—	-1,560
Other Financing Cash Flow
Total Cash Dividends Paid
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities	-12,238	44,914	20,616	14,217	11,213
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash	8,397	6,179	2,279	22,782	-3,631